



Living Cell Technologies Ltd

COMPANY ANNOUNCEMENT

Living Cell Technologies Receives Initial NaviGroup Funding

November 6, 2007- Melbourne, Australia and Auckland, New Zealand - Living Cell Technologies Limited (ASX:LCT; OTC:LVCLY.PK) today announced that U.S.-based investment group NaviGroup Management Ltd., has completed the initial closing under the Share Purchase Agreement it entered into with LCT as announced on October 3, 2007. NaviGroup has paid US\$2 million for the issue of 20,213,249 shares at A\$0.11 per share.

Under the terms of the agreement with NaviGroup, the Company will seek shareholder approval to grant to NaviGroup a 90-day option to subscribe for an additional US\$6 million at the lower of A\$0.20 per share or 80% of the 30-day average closing bid price per ordinary share of the Company.

The combination of these funds and the placement by Taylor Collison Limited, as announced on October 30, 2007, could raise up to A\$15 million for the Company. The terms of the Taylor Collison placement provide for up to 17.7 million ordinary shares to be issued at A\$0.36 per share, conditional upon shareholder approval at a general meeting of shareholders scheduled for November 27, 2007.

The combined funds place the Company in a strong financial position to further LCT's DiabeCell® clinical trials in Russia and New Zealand. The funding also allows the Company to further commercial development of DiabeCell®.

LCT's Chief Financial Officer, Richard Justice said, "We are very pleased with this initial placement as it will significantly increase our shareholder base and enhance our international profile. NaviGroup has strong international funding and business experience and a solid understanding of the diabetes market."

As a result of the latest closing, the holders of convertible notes issued by the company in June 2006 are entitled to receive options to purchase approximately 8.8 million shares in the Company at an exercise price of A\$0.01 per option. The noteholders are entitled to these options by way of compensation as a result of the Company raising capital (with NaviGroup) at less than the conversion price for the notes, namely A\$0.175 per share.

For further information: www.lctglobal.com

Paul Tan
CEO
Mob: 0402 716 984 (AUS)
021 608 784 (NZ)
Tel: +64 9 270 7941
ptan@lctglobal.com

Richard Justice
Tel: +64 9 276 2690
Mob: +64 21 223 4741
rjustice@lctglobal.com

Media Relations
Daniella Goldberg
Buchan Consulting
P: (612) 9237 2803
M: + 61 0416 211 067
dgoldberg@bcg.com.au

About Living Cell Technologies: www.lctglobal.com

Living Cell is developing live cell therapy products to treat life threatening human diseases. The company owns a biocertified pig herd that it uses as a source of cells for treating diabetes and neurological disorders. For patients with type 1 diabetes, the company transplants microencapsulated islet cells so that near-normal blood glucose levels may be achieved without

the need for administration of insulin or at significantly reduced levels. The company entered clinical trials for its diabetes product in 2007.

Further background information on the trial is available at

<http://www.lctglobal.com/news/167.php>

<http://www.lctglobal.com/news/149.php>

LCT disclaimer

This document contains certain forward-looking statements, relating to LCT's business, which can be identified by the use of forward-looking terminology, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management's expectations regarding the approval and commercialization of product candidates could be affected by, among other things, unexpected clinical trial results; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects.